MA33447B1 - Nouveau composé utilisé pour traiter les maladies dégénératives et inflammatoires - Google Patents
Nouveau composé utilisé pour traiter les maladies dégénératives et inflammatoiresInfo
- Publication number
- MA33447B1 MA33447B1 MA34555A MA34555A MA33447B1 MA 33447 B1 MA33447 B1 MA 33447B1 MA 34555 A MA34555 A MA 34555A MA 34555 A MA34555 A MA 34555A MA 33447 B1 MA33447 B1 MA 33447B1
- Authority
- MA
- Morocco
- Prior art keywords
- compound used
- inflammatory diseases
- novel compound
- diseases
- treat degenerative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention concerne un composé représenté par la formule (I). Ce composé peut être préparé comme une composition pharmaceutique, et peut être utilisé pour prévenir et traiter une variété d'états chez les mammifères, en particulier chez l'homme, comprenant à titre d'exemple notamment et de manière non restrictive, les états inflammatoires, les maladies auto-immunes, les maladies prolifératives, les rejets de transplantation, les maladies impliquant l'incapacité de renouvellement du cartilage, les malformations congénitales du cartilage, et/ou les maladies associées à l'hypersécrétion de IL6.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22068509P | 2009-06-26 | 2009-06-26 | |
US29818810P | 2010-01-25 | 2010-01-25 | |
PCT/EP2010/059067 WO2010149771A1 (fr) | 2009-06-26 | 2010-06-25 | Nouveau composé utilisé pour traiter les maladies dégénératives et inflammatoires |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33447B1 true MA33447B1 (fr) | 2012-07-03 |
Family
ID=42340530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34555A MA33447B1 (fr) | 2009-06-26 | 2010-06-25 | Nouveau composé utilisé pour traiter les maladies dégénératives et inflammatoires |
Country Status (38)
Country | Link |
---|---|
US (2) | US8796457B2 (fr) |
EP (2) | EP2792677B1 (fr) |
JP (1) | JP5486084B2 (fr) |
KR (1) | KR101712561B1 (fr) |
CN (1) | CN102459261B (fr) |
AR (1) | AR077221A1 (fr) |
AU (1) | AU2010264635B2 (fr) |
BR (1) | BRPI1014759A2 (fr) |
CA (1) | CA2765988C (fr) |
CL (1) | CL2011003276A1 (fr) |
CO (1) | CO6491039A2 (fr) |
CR (1) | CR20110673A (fr) |
CY (1) | CY1119711T1 (fr) |
DK (2) | DK2445912T3 (fr) |
DO (1) | DOP2011000378A (fr) |
EA (1) | EA020111B1 (fr) |
ES (2) | ES2519170T3 (fr) |
HK (2) | HK1168098A1 (fr) |
HR (2) | HRP20141057T1 (fr) |
HU (1) | HUE034205T2 (fr) |
IL (1) | IL216618A (fr) |
JO (1) | JO3030B1 (fr) |
LT (1) | LT2792677T (fr) |
MA (1) | MA33447B1 (fr) |
ME (1) | ME01916B (fr) |
MX (1) | MX2011013451A (fr) |
NZ (1) | NZ596836A (fr) |
PE (1) | PE20120494A1 (fr) |
PL (2) | PL2792677T3 (fr) |
PT (2) | PT2445912E (fr) |
RS (1) | RS53617B1 (fr) |
SG (1) | SG177359A1 (fr) |
SI (2) | SI2445912T1 (fr) |
SM (1) | SMT201400169B (fr) |
TW (1) | TWI469981B (fr) |
UY (1) | UY32741A (fr) |
WO (1) | WO2010149771A1 (fr) |
ZA (1) | ZA201109502B (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
WO2012142160A1 (fr) * | 2011-04-12 | 2012-10-18 | Rigel Pharmaceuticals, Inc. | Méthodes d'inhibition d'un rejet d'allogreffe |
TWI589299B (zh) * | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
KR20200039028A (ko) * | 2011-10-11 | 2020-04-14 | 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 | 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법 |
MX368511B (es) * | 2012-06-22 | 2019-10-07 | Galapagos Nv | Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma. |
JP6472803B2 (ja) | 2013-09-05 | 2019-02-20 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | トリアゾロピリジン化合物、その組成物及び使用方法 |
KR101930603B1 (ko) | 2013-12-05 | 2018-12-18 | 화이자 인코포레이티드 | 피롤로[2,3-d]피리미디닐, 피롤로[2,3-b]피라지닐 및 피롤로[2,3-d]피리디닐 아크릴아미드 |
GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
PL3283114T3 (pl) * | 2015-04-13 | 2024-01-03 | Galapagos Nv | Sposoby leczenia zaburzeń sercowo-naczyniowych |
US11414413B2 (en) | 2016-07-26 | 2022-08-16 | Suzhou Longbiotech Pharmaceuticals Co., Ltd. | Heterocyclic compound as JAK inhibitor, and salts and therapeutic use thereof |
WO2019149244A1 (fr) * | 2018-01-31 | 2019-08-08 | 南京明德新药研发股份有限公司 | Inhibiteur de jak et son utilisation |
KR20210049871A (ko) | 2018-08-29 | 2021-05-06 | 리제너론 파아마슈티컬스, 인크. | 류마티스성 관절염을 갖는 대상체를 치료하기 위한 방법 및 조성물 |
CN114206442A (zh) | 2019-01-31 | 2022-03-18 | 赛诺菲生物技术公司 | 用于治疗幼年特发性关节炎的抗il-6受体抗体 |
CN111072655B (zh) * | 2019-12-30 | 2021-12-10 | 深圳市坤健创新药物研究院 | 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用 |
US20230219889A1 (en) | 2020-05-19 | 2023-07-13 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
US11596612B1 (en) | 2022-03-08 | 2023-03-07 | PTC Innovations, LLC | Topical anesthetics |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2228451T3 (es) | 1999-01-29 | 2005-04-16 | Chugai Seiyaku Kabushiki Kaisha | Promotores de condrogenesis y derivados de indolin-2-ona. |
EP1391211A1 (fr) | 2001-04-27 | 2004-02-25 | Chugai Seiyaku Kabushiki Kaisha | Promoteurs de la chondrogenese |
US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
CA2487679A1 (fr) * | 2002-05-30 | 2003-12-11 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de proteines kinases jak et cdk2 |
WO2004072072A1 (fr) | 2003-02-14 | 2004-08-26 | Pfizer Products Inc. | Triazolo-pyridines utilisees comme composes anti-inflammatoires |
US20050222171A1 (en) * | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
EP2386856B1 (fr) | 2004-06-21 | 2013-07-24 | Galapagos N.V. | Procédés et moyens pour le traitement de l'arthrose |
MX2007002050A (es) | 2004-08-18 | 2007-03-29 | Pharmacia & Upjohn Co Llc | Compuestos de triazolopiridina. |
WO2006038116A2 (fr) | 2004-10-07 | 2006-04-13 | Warner-Lambert Company Llc | Agents antibacteriens |
GB0515026D0 (en) | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
AU2007291190A1 (en) * | 2006-08-30 | 2008-03-06 | Cellzome Limited | Triazole derivatives as kinase inhibitors |
WO2008150015A1 (fr) | 2007-06-05 | 2008-12-11 | Takeda Pharmaceutical Company Limited | Composés hétérobicycliques comme inhibiteurs de kinase |
CN101801966A (zh) | 2007-07-18 | 2010-08-11 | 诺瓦提斯公司 | 双环杂芳基化合物和它们作为激酶抑制剂的用途 |
WO2009017954A1 (fr) * | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibiteurs de kinase jak2 |
EP2181112A1 (fr) | 2007-08-31 | 2010-05-05 | Merck Serono S.A. | Composés de triazolopyridine et leur utilisation comme inhibiteurs de ask |
GB0719803D0 (en) * | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
US20090217316A1 (en) * | 2008-02-22 | 2009-08-27 | Binita Gupta | Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service |
PE20110063A1 (es) | 2008-06-20 | 2011-02-16 | Genentech Inc | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK |
WO2010010187A1 (fr) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires |
WO2010010184A1 (fr) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4]triazolo[1, 5-a]pyridines utilisées comme inhibiteurs de jak |
WO2010010189A1 (fr) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires |
WO2010010188A1 (fr) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires |
JO3041B1 (ar) * | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
WO2010010186A1 (fr) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires |
CN102459258B (zh) | 2009-06-05 | 2015-11-25 | 赛福伦公司 | 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途 |
JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
TWI462920B (zh) * | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
-
2010
- 2010-05-31 JO JOP/2010/0179A patent/JO3030B1/ar active
- 2010-06-23 TW TW99120587A patent/TWI469981B/zh not_active IP Right Cessation
- 2010-06-24 AR ARP100102236A patent/AR077221A1/es active IP Right Grant
- 2010-06-25 MX MX2011013451A patent/MX2011013451A/es active IP Right Grant
- 2010-06-25 NZ NZ596836A patent/NZ596836A/xx not_active IP Right Cessation
- 2010-06-25 ES ES10728648.6T patent/ES2519170T3/es active Active
- 2010-06-25 EP EP14175887.0A patent/EP2792677B1/fr active Active
- 2010-06-25 PL PL14175887T patent/PL2792677T3/pl unknown
- 2010-06-25 RS RS20140614A patent/RS53617B1/en unknown
- 2010-06-25 PE PE2011002144A patent/PE20120494A1/es active IP Right Grant
- 2010-06-25 AU AU2010264635A patent/AU2010264635B2/en not_active Ceased
- 2010-06-25 BR BRPI1014759A patent/BRPI1014759A2/pt active Search and Examination
- 2010-06-25 PT PT107286486T patent/PT2445912E/pt unknown
- 2010-06-25 PL PL10728648T patent/PL2445912T3/pl unknown
- 2010-06-25 WO PCT/EP2010/059067 patent/WO2010149771A1/fr active Application Filing
- 2010-06-25 UY UY0001032741A patent/UY32741A/es not_active Application Discontinuation
- 2010-06-25 DK DK10728648.6T patent/DK2445912T3/da active
- 2010-06-25 CN CN201080028413.0A patent/CN102459261B/zh active Active
- 2010-06-25 PT PT141758870T patent/PT2792677T/pt unknown
- 2010-06-25 LT LTEP14175887.0T patent/LT2792677T/lt unknown
- 2010-06-25 HU HUE14175887A patent/HUE034205T2/en unknown
- 2010-06-25 ES ES14175887.0T patent/ES2634325T3/es active Active
- 2010-06-25 MA MA34555A patent/MA33447B1/fr unknown
- 2010-06-25 SG SG2011096179A patent/SG177359A1/en unknown
- 2010-06-25 KR KR1020127002060A patent/KR101712561B1/ko active IP Right Grant
- 2010-06-25 SI SI201030775T patent/SI2445912T1/sl unknown
- 2010-06-25 EP EP10728648.6A patent/EP2445912B1/fr active Active
- 2010-06-25 JP JP2012516762A patent/JP5486084B2/ja active Active
- 2010-06-25 ME MEP-2014-132A patent/ME01916B/me unknown
- 2010-06-25 DK DK14175887.0T patent/DK2792677T3/en active
- 2010-06-25 SI SI201031494T patent/SI2792677T1/sl unknown
- 2010-06-25 US US12/823,682 patent/US8796457B2/en active Active
- 2010-06-25 EA EA201270076A patent/EA020111B1/ru not_active IP Right Cessation
- 2010-06-25 CA CA2765988A patent/CA2765988C/fr not_active Expired - Fee Related
-
2011
- 2011-11-27 IL IL216618A patent/IL216618A/en not_active IP Right Cessation
- 2011-12-06 DO DO2011000378A patent/DOP2011000378A/es unknown
- 2011-12-14 CR CR20110673A patent/CR20110673A/es unknown
- 2011-12-22 CL CL2011003276A patent/CL2011003276A1/es unknown
- 2011-12-22 ZA ZA2011/09502A patent/ZA201109502B/en unknown
-
2012
- 2012-01-16 CO CO12005375A patent/CO6491039A2/es active IP Right Grant
- 2012-09-11 HK HK12108855.3A patent/HK1168098A1/xx not_active IP Right Cessation
- 2012-09-11 HK HK15103046.1A patent/HK1202537A1/xx not_active IP Right Cessation
-
2014
- 2014-08-04 US US14/451,127 patent/US9505754B2/en active Active
- 2014-11-03 HR HRP20141057AT patent/HRP20141057T1/hr unknown
- 2014-11-10 SM SM201400169T patent/SMT201400169B/xx unknown
-
2017
- 2017-07-04 HR HRP20171024TT patent/HRP20171024T1/hr unknown
- 2017-07-24 CY CY20171100784T patent/CY1119711T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33447B1 (fr) | Nouveau composé utilisé pour traiter les maladies dégénératives et inflammatoires | |
MA33448B1 (fr) | 5-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl-carboxamides utilises en tant qu'inhibiteurs de jak | |
MX2013012281A (es) | Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias. | |
MA20150065A1 (fr) | Nouveaux dérivés d'acide indanyloxydihydrobenzofurannylacétique et leur utilisation comme agonistes du récepteur gpr40 | |
EP2086540B8 (fr) | Composés de triazolopyridine pour le traitement de maladies dégénératives et inflammatoires | |
MA35153B1 (fr) | Immunoconjugués, compositions les contenant, et procédés de préparation et d'utilisation correspondants | |
MA34300B1 (fr) | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 | |
MA35419B1 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
MX354134B (es) | Derivados de acido 1,2,3,4-tetrahidrociclopenta [b] indol-3-il) acetico sustituidos utiles en el tratamiento de enfermedades autoinmune e inflamatorias. | |
RS20090137A (en) | Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists | |
BRPI0606476A2 (pt) | compostos para inflamação e usos imuno-relacionados e suas composições farmacêuticas | |
MA34820B1 (fr) | Ligandise se liant au récepteur ii du tgf-bêta | |
MX2009013733A (es) | Nuevos derivados de acido dicarboxilico como agonistas de los receptores de s1p1. | |
MX2020003863A (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios. | |
MA35012B1 (fr) | Composition phytosanitaire comprenant des huiles essentielles renforçant l'activité anti-fongique | |
MA41238A (fr) | Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit | |
MA37775A1 (fr) | Aminotriazolopyridine pour l'utilisation dans le traitement de l'inflammation, et compositions pharmaceutiques associées | |
WO2011011882A8 (fr) | Acides gras hydroxy et leurs utilisations dans le traitement et le diagnostic de maladies | |
MA34308B1 (fr) | Triazolopyridines substituées | |
PH12016501677A1 (en) | Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
PH12019501853A1 (en) | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
MX349788B (es) | Peptidomimeticos fijados a plantilla como inhibidores de receptor de formil-peptido 1. | |
MA35102B1 (fr) | Dérivés d'acide 7-(hétéroaryl-amino)-6,7,8,9-tétrahydropyrido[1,2-a]indolacétique et leur utilisation en tant que modulateurs du récepteur aux prostaglandines d2 | |
WO2009007827A3 (fr) | Nouveaux esters de diclofénac et utilisations de ceux-ci | |
MA35860B1 (fr) | Dérivés de quinoléine en tant qu'inhibiteurs d'enzyme pde10a |